Table 4 Baseline and postinterventional concentrations of vasoconstrictors, tissue factor, and TNFα
From: Coronary aspirate TNFα reflects saphenous vein bypass graft restenosis risk in diabetic patients
With DM | Without DM | |||
|---|---|---|---|---|
Coronary arterial plasma | Coronary aspirate plasma | Coronary arterial plasma | Coronary aspirate plasma | |
catecholamines, n = 12 / 12 | ||||
epinephrine [nmol/L] | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 |
norepinephrine [nmol/L] | 3.2 ± 0.8 | 3.7 ± 0.6 | 3.4 ± 0.9 | 4.1 ± 1.3 |
endothelin [pmol/L], n = 15 / 16 | 1.4 ± 0.6 | 1.3 ± 0.5 | 1.9 ± 0.6 | 1.7 ± 0.6 |
serotonin [μmol/L], n = 15 / 16 | 0.5 ± 0.2 | 0.9 ± 0.4† | 0.4 ± 0.1 | 1.1 ± 0.5† |
thromboxane B 2 [pmol/L], n = 15 / 16 | 46 ± 7 | 95 ± 9† | 51 ± 8 | 82 ± 13† |
tissue factor [pmol/L], n = 15 / 16 | 8.6 ± 0.5 | 8.7 ± 0.6 | 9.6 ± 1.0 | 8.8 ± 0.8 |
TNFα [pmol/L], n = 15 / 16 | 1.1 ± 0.3 | 2.2 ± 0.7*, † | 0.5 ± 0.2 | 1.1 ± 0.2† |